TIVC
Valion Bio, Inc.
Key Financials
Gross Profit
$2000
↓ 99.3%
Net Income
$-8878000
↓ 57.0%
Revenue
$302000
N/A
Operating Income
$-7898000
↓ 39.5%
EPS (Diluted)
$-19.68
↓ 89.2%
Total Liabilities
$7.4M
↑ 2635.3%
Total Assets
$31.6M
↑ 1026.0%
Shareholders' Equity
$16.8M
↑ 392.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| EFFECT | 8/12/2026 | View on SEC |
| SCHEDULE 13D/A | 8/11/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13D | 8/3/2026 | View on SEC |
| DEF 14A | 7/17/2026 | View on SEC |
| S-1 | 7/17/2026 | View on SEC |
| SCHEDULE 13G | 7/17/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TIVC |
| Company Name | Valion Bio, Inc. |
| CIK | 1787740 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (888)276-6888 |